Key result
Each 1.5-fold increase in ADMA at 2 months following doxorubicin initiation was associated with an increased hazard of cancer therapeutics-related cardiac dysfunction.
Why the study?
Oxidative/nitrosative stress and endothelial dysfunction are hypothesized to drive cancer therapeutics-related cardiac dysfunction, but the relationship with circulating arginine-nitric oxide metabolites was unstudied.
Do early changes in arginine-NO metabolites predict cancer therapeutics-related cardiac dysfunction in breast cancer patients treated with doxorubicin?
Cohort (n=170)
Blinded outcome assessment
No
Do early changes in arginine-NO metabolites predict cancer therapeutics-related cardiac dysfunction in breast cancer patients treated with doxorubicin?
Answers are grounded in this paper and cite their sources.
Early increases in ADMA and MMA following doxorubicin therapy are associated with a higher risk of cancer therapeutics-related cardiac dysfunction, highlighting their potential as predictive biomarkers.
Background Oxidative/nitrosative stress and endothelial dysfunction are hypothesized to be central to cancer therapeutics-related cardiac dysfunction (CTRCD). However, the relationship between circulating arginine-nitric oxide (NO) metabolites and CTRCD remains unstudied. Objectives To examine the relationship between arginine-NO metabolites and CTRCD in a prospective cohort of 170 breast cancer patients treated with doxorubicin ± trastuzumab. Methods Plasma levels of arginine, citrulline, ornithine, asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and N-monomethylarginine (MMA) were quantified at baseline, 1 month, and 2 months following doxorubicin initiation. Determinants of baseline biomarker levels were identified using multivariable linear regression, and Cox regression defined the association between baseline levels and 1- or 2-month biomarker changes and CTRCD rate in 139 participants with quantitated echocardiograms at all time points. Results Age, hypertension, body mass index, and African American race were independently associated with ≥1 baseline citrulline, ADMA, SDMA, and MMA levels. Decreases in arginine and citrulline, and increases in ADMA were observed at 1 and 2 months (all P<0.05). Overall, 32 participants experienced CTRCD over a maximum follow-up of 5.4 years. Hazard ratios for ADMA and MMA at 2 months were 3.33 (95% confidence interval [CI] 1.12, 9.96) and 2.70 (95%CI 1.35, 5.41), respectively, and 0.78 (95%CI 0.64, 0.97) for arginine at 1 month. Conclusions In breast cancer patients undergoing doxorubicin therapy, early alterations in arginine-NO metabolite levels occurred, and early biomarker changes were associated with a greater CTRCD rate. Our findings highlight the potential mechanistic and translational relevance of this pathway to CTRCD.
No takes yet. Share an insight, caveat, or question.
Finkelman et al. (2017) conducted a cohort in Breast cancer (n=170). Early changes in arginine-NO metabolites (ADMA) vs. Baseline levels was evaluated on Cancer therapeutics-related cardiac dysfunction (CTRCD) (LVEF reduction ≥10% to <50%) (HR 3.33, 95% CI 1.12-9.96). Each 1.5-fold increase in ADMA at 2 months following doxorubicin initiation was associated with an increased hazard of cancer therapeutics-related cardiac dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: